Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy

The authors are commenting on the article entitled “Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy” published by Sheptulinet al. in Graefes Archive for Clinical and Experimental Ophthalmology; http:/dx.doi.org/10.1007/s00417-018-4086-6. Published online August 10, 2018.The authors concluded that the duration of the symptoms from the chronic central serous chorioretinopathy diagnosis to photodynamic therapy, pigment epithelial detachment, and best-corrected visual acuity before treatment significantly correlated with an achievement of the photodynamic therapy effect. However, the validation, extrapolation, and generalizability of these outcomes can be made only after inclusion in the multivariate stepwise regression analysis of all the missing baseline potential predictive factors mentioned by us in addition to the baseline characteristics already assessed in this study, which serve as potential prognosticators influencing functional and anatomic improvements.